Zhang Sanquan, Xu Xiao, Liu Yumei, Xue Rujun, Li Changxing, Chen Pingjiao, Zhang Xibao, Liang Jingyao
Institute of Dermatology, Guangzhou Medical University, Guangzhou, People's Republic of China.
Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, People's Republic of China.
Dermatol Ther. 2020 May;33(3):e13390. doi: 10.1111/dth.13390. Epub 2020 Apr 25.
Most available options for the treatment of warts are limited by the potential for scarring, pain, lack of response, or recurrences, and the patients are often unable to tolerate and accept those experiences. The aim of this study was to evaluate the clinical efficacy and safety of oral systemic acitretin monotherapy in patients with extensive/recalcitrant cutaneous warts. The patients were given a dose of acitretin of 0.8 mg kg day , and the clinical efficacy and safety of acitretin was assessed every 2 weeks for 2 months. A total of 14 patients (12 males and 2 females) were included, with an age of 14-60 years (mean 33 ± 14.7 years) and a course of 4-48 months (mean 21.6 ± 13.4 months). After 2 months of acitretin treatment, 42.9% (6/14) of patients (including warts of the feet, legs, and hands) exhibited complete response, 28.6% (4/14) excellent response, and 28.6% (4/14) good response. All patients demonstrated significant improvement, and the drug was well tolerated, with no patients discontinuing therapy due to side effects. Common mild side effects included dry skin and cheilitis. There were no recurrences during a follow-up period of 6 months. Acitretin monotherapy is an effective, safe, and well-tolerated treatment for patients with extensive/recalcitrant cutaneous warts who are unsuitable for or unwilling to accept traditional treatment methods.
大多数现有的疣治疗方法都受到潜在的瘢痕形成、疼痛、无反应或复发的限制，患者往往无法耐受和接受这些情况。本研究的目的是评估口服阿维A单一疗法治疗广泛性/顽固性皮肤疣患者的临床疗效和安全性。给予患者阿维A剂量为0.8mg/kg/天，每2周评估阿维A的临床疗效和安全性，持续2个月。共纳入14例患者（12例男性和2例女性），年龄14 - 60岁（平均33±14.7岁），病程4 - 48个月（平均21.6±13.4个月）。阿维A治疗2个月后，42.9%（6/14）的患者（包括足部、腿部和手部的疣）表现为完全缓解，28.6%（4/14）为优效反应，28.6%（4/14）为良好反应。所有患者均有显著改善，药物耐受性良好，无患者因副作用而停药。常见的轻度副作用包括皮肤干燥和唇炎。在6个月的随访期内无复发。对于不适合或不愿意接受传统治疗方法的广泛性/顽固性皮肤疣患者，阿维A单一疗法是一种有效、安全且耐受性良好的治疗方法。
